Answers are grounded in this paper and cite their sources.
In vitro and tissue analysis demonstrates that KIAA1429-stabilized LINC00958 accelerates glycolysis in gastric cancer, indicating a promising metabolic therapeutic target.
Emerging evidence has demonstrated that N 6 ‐methyladenosine (m 6 A) and long noncoding RNAs (lncRNAs) are both crucial regulators in gastric cancer (GC) tumorigenesis. However, the interaction of m 6 A and lncRNAs in GC progression are still unclear. Here, our team discovered that lncRNA LINC00958 expression up‐regulated in GC tissue and cells. Clinically, high‐expression of LINC00958 was clinically correlated to lower survival of GC patients. Functionally, in vitro assays demonstrated that LINC00958 promoted the GC cells' aerobic glycolysis. Mechanistically, methylated RNA immunoprecipitation sequencing (MeRIP‐Seq) found that there were m 6 A‐modificated sites in LINC00958, and moreover m 6 A methyltransferase KIAA1429 catalyzed the m 6 A modification on LINC00958 loci. Moreover, LINC00958 interacted with GLUT1 mRNA via the m 6 A‐dependent manner to enhance GLUT1 mRNA transcript stability, thereby positively regulating the aerobic glycolysis of GC. In conclusion, our findings reveal the function and mechanism of KIAA1429‐induced LINC00958 in GC, delineating novel understanding of m 6 A‐lncRNA in cancer biology.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: